Vermillion, Inc. (VRML) Price Target Raised to $2.25 at Canaccord Genuity
Vermillion, Inc. (NASDAQ:VRML) had its price objective upped by Canaccord Genuity from $1.75 to $2.25 in a research report sent to investors on Thursday. The brokerage currently has a buy rating on the stock.
Separately, ValuEngine cut Vermillion from a hold rating to a sell rating in a research note on Friday, July 28th.
Vermillion (NASDAQ VRML) traded up $0.07 on Thursday, reaching $1.74. The company had a trading volume of 34,319 shares, compared to its average volume of 104,852. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.21 and a quick ratio of 3.16.
Vermillion (NASDAQ:VRML) last released its earnings results on Wednesday, August 9th. The company reported ($0.04) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The business had revenue of $0.90 million for the quarter. Vermillion had a negative return on equity of 215.26% and a negative net margin of 372.05%.
ILLEGAL ACTIVITY NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and republished in violation of United States and international copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/vermillion-inc-vrml-price-target-raised-to-2-25-at-canaccord-genuity/1681427.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Vermillion by 0.7% in the second quarter. Vanguard Group Inc. now owns 580,484 shares of the company’s stock valued at $1,068,000 after acquiring an additional 4,200 shares during the last quarter. Essex Investment Management Co. LLC increased its stake in Vermillion by 145.8% in the third quarter. Essex Investment Management Co. LLC now owns 216,607 shares of the company’s stock valued at $390,000 after acquiring an additional 128,494 shares during the last quarter. Finally, Birchview Capital LP increased its stake in Vermillion by 7.9% in the third quarter. Birchview Capital LP now owns 2,462,933 shares of the company’s stock valued at $4,433,000 after acquiring an additional 180,000 shares during the last quarter. 35.55% of the stock is currently owned by institutional investors and hedge funds.
Vermillion Company Profile
Vermillion, Inc is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician’s clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery.
Receive News & Ratings for Vermillion Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.